PT  - JOURNAL ARTICLE
AU  - Simone Weber
AU  - Victoria Kehl
AU  - Johanna Erber
AU  - Karolin I. Wagner
AU  - Ana-Marija Jetzlsperger
AU  - Theresa Burrell
AU  - Kilian Schober
AU  - Philipp Schommers
AU  - Max Augustin
AU  - Claudia S. Crowell
AU  - Markus Gerhard
AU  - Christof Winter
AU  - Christoph D. Spinner
AU  - Ulrike Protzer
AU  - Dieter Hoffmann
AU  - Elvira D’Ippolito
AU  - Dirk H Busch
TI  - CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
AID  - 10.1101/2021.12.22.21268268
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.22.21268268
4099  - http://medrxiv.org/content/early/2021/12/24/2021.12.22.21268268.short
4100  - http://medrxiv.org/content/early/2021/12/24/2021.12.22.21268268.full
AB  - Background COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, severe COVID-19 often occurs in the absence of obvious comorbidities. Guided by the finding of cytomegalovirus (CMV)-specific T cells with some cross-reactivity to SARS-CoV-2 in a COVID-19 intensive care unit (ICU) patient, we decided to investigate whether CMV seropositivity is associated with severe or critical COVID-19.Methods National German COVID-19 bio-sample and data banks were used to retrospectively analyze the CMV serostatus of patients who experienced mild (n=101), moderate (n=130) or severe to critical (n=80) disease by CMV IgG serology. We then investigated the relationship between disease severity and CMV serostatus via statistical models.Results Non-geriatric patients (< 70 years) with severe COVID-19 were found to have a very high prevalence of CMV-seropositivity, while CMV status distribution in individuals with mild disease was similar to the prevalence in the German population; interestingly, this was not detectable in older patients. Prediction models support the hypothesis that the CMV serostatus might be a strong biomarker in identifying younger individuals with a higher risk of developing severe COVID-19.Conclusions We identified ‘CMV-seropositivity’ as a potential novel risk factor for severe COVID-19 in non-geriatric individuals in the studied cohorts. More mechanistic analyses as well as confirmation of similar findings in cohorts representing the currently most relevant SARS-CoV-2 variants should be performed shortly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the EIT Health CoViproteHCt #20877 and the German National Network of University Medicine of the Federal Ministry of Education and Research (BMBF; NaFoUniMedCovid19, 01KX2021; COVIM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the study design and sample collection was obtained from the local ethics committee of the Technical University of Munich (reference number 182/20 and 633/21 S-SR) and the COVIM steering committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors